Muneeswar Gupta Nittala, None;
wenying fan, None;
Swetha Bindu Velaga, None;
Shaun Lampen, None;
Michael Ip, Allergan (C), Astellas Institute for Regenerative Medicine (C), Boehringer Ingelheim (C), Genentech (C), Omeros (C), Quark (C), Thrombogenics (C);
Charles Wykoff, Aerpio Therapeutics (F), Alcon Laboratories, Inc. (C), Alimera Sciences, Inc. (C), Allergan, Inc. (C), Alnylam Pharmaceuticals (C), Atheneum Partners (C), Bayer AG (C), Clearside Biomedical, Inc. (C), Consultants LLC (C), CORCEPT (C), D.O.R.C. International (C), Destum Partners Inc. (C), dverum Biotechnologies, Inc (F), Genentech, Inc. (C), Hexal AG (C), k2c Medical Communications (C), Notal Vision (C), Novo Nordisk (C), ONL Therapeutics, Inc. (C), Regeneron Pharmaceuticals, Inc. (C), Roche (C), Santen Inc. (C), System Analytic (C), ThromboGenics NV. (C), Valeant Pharmaceuticals International, Inc. (C);
Srinivas Sadda, Allergan (F), Allergan (C), Carl Zeiss Meditec (F), CenterVue (C), Genentech (C), Genentech (F), Heidelberg Engineering (C), Iconic (C), NightstarX (C), Novartise (C), Optos (F), Thrombogenics (C), Topcon (C)